؉ T-cell response against hepatitis C virus (HCV) is critical for control of the chronicity of HCV infection. The ability of HCV structural protein endogenously expressed in an antigenpresenting cell (APC) to be presented by class II major histocompatibility complex molecules to CD4 ؉ T cells was investigated by in vitro culture analyses using HCV core-specific T 
Hepatitis C virus (HCV) has been known as a major etiologic agent of posttransfusion and sporadic community-acquired non-A, non-B hepatitis. Like the other members in the family Flaviviridae, HCV contains a single, positive-strand RNA genome with a single long open reading frame (ORF) coding for a polyprotein precursor of about 3,000 amino acids (aa) (12) . HCV infection is frequently persistent in the majority of patients and is closely associated with the later development of liver cirrhosis and hepatocellular carcinoma (3, 12, 16, 32) . The effective control of HCV infection has been limited by the high frequency of viral genetic heterogeneity (7), the low rate of response to alpha interferon (46) , and inadequate production of protective immunity (44, 45) . These features strongly suggest that there is a great need to establish a new, highly effective therapy. CD4 ϩ T cells are considered to play a central role in the generation of protective immunity against infections, because they can provide help to B cells for antibody production (42) and to cytotoxic precursor T cells for their maturation to effectors (21) . Some CD4 ϩ T cells may also act as cytotoxic effectors (30) . It has been recognized that CD4
ϩ T-cell response to HCV antigens is important for determining the clinical course of HCV infection (17, 37) . Generally, T-cell proliferation is more frequent and stronger in patients with a benign course (6, 17, 20, 33, 37) that is accompanied by the normalization of serum alanine aminotransferase and, in some cases, the clearance of viral RNA (17, 37) . In contrast, patients who have a poor T-cell response tend to develop persistent infection (17, 37) . These findings support the hypothesis that a sufficient CD4 ϩ T-lymphocyte response is critical for limiting HCV infection.
Activation of T lymphocytes depends on the recognition of processed viral peptides, but not native antigens, in the context of major histocompatibility complex (MHC) molecules that are presented by antigen-presenting cells (APCs) (56) . The B cell is an important professional APC, and its role in mediating antigen-specific immune response has been described extensively (11) . Epstein-Barr virus (EBV)-transformed B-lymphoblastoid cells are frequently used as APCs in in vitro analyses for antigen processing and presentation to T cells. These cells are characterized by high-level expression of class I and class II MHC molecules, along with accessory molecules such as ICAM-1, B7/BB1, and LFA-3, known to be important costimulatory molecules for T-cell activation (9, 15, 24) . Importantly, transfected EBV-immortalized B cells expressing a tumor antigen have been shown to be capable of eliciting both T-helper and cytotoxic-T-lymphocyte (CTL) responses following in vivo inoculation (40) . Nevertheless, dendritic cells have been shown to be critical for initiating responses by naive T cells (53) , and in some situations presentation by B cells has been suggested to be toleragenic (35) . To date, the role of B cells in processing and presenting HCV antigens has not been studied in detail and the mechanisms underlying T-cell-B-cell interaction are still being worked out.
In the present study, EBV-transformed B-lymphoblastoid cell lines (B-LCLs) established from HCV-infected patients were transfected with an expression vector coding for the whole structural region and part of the NS2 region of the HCV genome. The capacity of transfected B-LCL APCs for presenting intracellularly synthesized peptides was assessed by in vitro induction of the HCV-specific lymphoproliferative response of autologous T-cell lines. Our results indicated that core protein was properly expressed and efficiently presented by B-LCL APCs to CD4
ϩ T cells. We demonstrated that the endogenous core peptides were presented through the class II MHC pathway and that they need B7/BB1 for providing costimulatory signals. 7 cells were mixed with 40 g of pCMV980 or pcDNA3/CAT in 0.8 ml of the same medium, then transferred to a 0.40-cm cuvette for electroporation using a Gene Pulser (Bio-Rad, Richmond, Calif.). The optimal conditions of 0.3 kV and 960 F were predetermined to produce maximal CAT activity at 48 h posttransfection (by an ELISA; Boehringer Mannheim). After electric pulsing, the cell suspension was transferred to 0.8 ml of the growth medium in which the cells had been growing previously. Transfected cells were allowed to grow for 48 h; then they were used either for transient expression assays by immunofluorescence (IF) and immunoblotting or for establishing stable expression cell lines. In the latter case, the cells were cultured in complete medium for an additional 2 weeks in the presence of 400 g of geneticin (GIBCO BRL)/ml. The positive selected cell lines were maintained in complete medium containing 200 g of geneticin/ml. All transfectants were restimulated with antibody to human immunoglobulin M (IgM) (chain) [F(abЈ) 2 ] (Caltag Laboratories, Burlingame, Calif.) at 10 g/ml for 24 h before they were used as APCs. COS7 cells were transfected with the same plasmids by using Lipofectin (GIBCO BRL) according to the manufacturer's instructions. The cells were harvested at 48 h posttransfection for analyses by IF and immunoblotting or were cultured continuously in the selection medium in order to generate a stable expression cell line, as mentioned above.
IF and immunoblotting. Mouse monoclonal antibody (MAb) specific for HCV core protein (H-29) was a kind gift from A. Takamizawa. Mouse MAbs specific for HCV E1 (A4) and E2 (A11) were generously provided by S. M. Feinstone. For IF, the transfected cells were harvested at 48 h posttransfection, washed with phosphate-buffered saline (PBS), and fixed with cold acetone (Ϫ20°C) on glass slides. Nonspecific binding sites were blocked with normal goat serum at 20% (for B-LCLs) or 5% (for COS7 cells) in PBS containing 0.1% saponin. The cells were incubated with anti-core antibody for 1 h, and specific binding was detected by fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG F(abЈ) 2 (Leinco Technologies Inc., Ballwin, Mo.). All procedures were carried out at room temperature. Observation was performed with an Orthoplan universal large-field microscope (Leica GmbH, Wetzlar, Germany) or an LSM-GB200 confocal laser microscopy (Olympus Corp., Tokyo, Japan). For sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblot analyses, the transfected cells were harvested at 48 h posttransfection and washed as described above. The cell pellet was resuspended in 100 l of 250 mM Tris-HCl buffer (pH 7.8) and homogenized with a micro-tissue grinder (Wheaton, N.J.) on ice. Analysis of proteins by SDS-PAGE and immunoblotting was performed as described elsewhere (10) .
Synthetic peptides. HCV core peptides C2 (aa 45 to 60), C3 (aa 63 to 83), C6 (aa 117 to 133), C9 (aa 153 to 168), and C10 (aa 162 to 177) were synthesized as described previously (51) . All peptides were soluble in PBS at a concentration of 1 mM and were stocked in aliquots at Ϫ20°C until use.
PBMC-derived T-cell lines. To establish core-specific T-cell lines, 2 ϫ 10 6
PBMCs were cultured in 1 ml of complete medium in 1 well of a 24-well culture plate (Costar). HCV core peptides C2, C3, C6, C9, and C10 were added in a mixture at the initiation of the culture to give a final concentration of 1 M for each peptide. Some of these peptides were capable of inducing T-lymphocyte (CD4 ϩ ) proliferation in HCV-infected patients (3a), but they were ineffective in restimulating primed CD4 Ϫ CD8 ϩ CTLs in mice (51) . After 7 days, sensitized T cells were expanded by adding recombinant interleukin 2 (IL-2) (50 U/ml; Genzyme) to the cultures. Two weeks later, the cultures were tested for T-cell line 3 H incorporation in DNA was measured 16 to 18 h later with a liquid scintillation counter (Aloka). The data were expressed as counts per minute (mean value of triplicate wells Ϯ standard deviation [SD]) or stimulation indices (SI). SI was calculated as (counts per minute of T-cell responders ϩ APCs)/(counts per minute of T-cell responders ϩ medium alone). Only an SI value greater than 4 was considered a positive response. In all experiments, B-LCL APCs, either transfected or untransfected, were treated with MMC at 100 g/ml for 30 min at 37°C, followed by three washes with complete medium prior to culture with T cells (51) .
Leupeptin treatment. APCs (2 ϫ 10 6 cells/ml) were preincubated with various concentrations of leupeptin (Sigma Chemical Co., St. Louis, Mo.) for 24 h and then used for a T-cell proliferative assay in the presence of the same doses of leupeptin.
Phenotype analysis. T cells cultured for 48 h with autologous APCs were incubated for 1 h at 4°C in the presence of MAbs to CD4 (OKT4) and CD8 (OKT8) (both from Ortho Diagnostic Systems Inc., Raritan, N.J.) alone or together at 10 g/ml, or in the absence of antibody. Subsequently, complement (Low-Tox-H; Cedarlane Laboratories Ltd.) was added at a 1:15 dilution and incubated for 1 h at 37°C. The dead versus viable cells were sorted by trypan blue staining. Maximum cytolysis referred to the percentage of cytolysis in the presence of both anti-CD4 and anti-CD8 antibodies and complement. 
RESULTS
Characterization of structural gene products of HCV. The translational products from pC980 have been expressed previously by using an in vitro expression system in the presence of microsomal membranes with [
35 S]methionine for labeling, showing four major cleavage proteins of 70, 35, 22, and 19 kDa that are relevant to the E2, E1, core, and NS2A regions of the HCV ORF, respectively (29) . In this study, the same HCV cDNA sequence was subcloned into the pCMV980 expression vector and expressed intracellularly in COS7 and B-LCL cells. Analyses of cell lysates from transiently (48 h) transfected COS7 and B-LCL cells by SDS-PAGE and immunoblotting revealed results similar to those obtained by in vitro expression (29) (Fig. 1) . Three major bands, of 70, 35, and 22 kDa, were identified by using MAbs to E2 (A11), E1 (A4), and core protein (H-29), respectively (Fig. 1a) . The supernatants of B-LCL980 cultures (2 ϫ 10 6 cells/ml) over different times were also tested for the presence of core protein by immunoblotting. No sample showed a positive result, indicating that the concentration of core protein in the medium might be very low, at least below the detection level of this assay (Fig. 1b) .
Expression and localization of core protein. Expression of core protein in transfected COS cells and B-LCL APCs was probed with H-29. The signal of staining was generally stronger in COS cells than in B-cell APCs ( Fig. 2A and B) . Both cells showed a cytoplasmic staining pattern. The core products were usually diffused throughout the cytoplasm, with some large granules or patches predominant in the perinuclear region. The core protein was seldom stained in the nuclei during transient expression. The intracellular localization of HCV core protein was further assessed by double immunostaining. A polyclonal anti-core IgG fraction was prepared from the serum of an HCV-infected patient who had a high titer of anti-core protein antibody. The specificity of the antibody to core protein but not to envelope proteins was confirmed by immunoblot analysis (data not shown). The IgG fraction was then labeled with digoxigenin with the Dig Antibody Labeling kit (Boehringer Mannheim Biochemica). Specific binding was detected by fluorescein-labeled goat anti-digoxigenin Fab (Boehringer Mannheim Biochemica). A mouse MAb to prolyl 4-hydroxylase (PDI) (Fuji Yakuhin Kogyo Co., Ltd., Toyama, Japan), an intrinsic endoplasmic reticulum (ER) membrane protein (41) , was used for distinguishing ER and detected by goat anti-mouse IgG F(abЈ) 2 conjugated with Texas red (Leinco Technologies Inc.). By double immunostaining, the IF pattern of the core protein was well colocalized with that of the ER (Fig. 2C) . For each independent experiment, negative cell controls (untransfected cells, or cells transfected with pcDNA3/ CAT) and antibody controls (pools of normal human or mouse sera, or goat polyclonal antibody to CAT; Boehringer Mannheim Biochemica) were included. Nonspecific binding was not noticed in our assays (data not shown).
Efficient induction of T-cell proliferation by B-LCL APCs. Stable B-LCL980 transfectants were obtained from all three patients and subsequently used to stimulate autologous T cells after MMC treatment. By using B-LCL980 APCs, strong T-cell proliferation was induced in two of three patients (Fig. 3) . The level of response to antigens expressed by B-LCL980 was highest in patient P1 (28, ) . No proliferative responses above background levels to CAT or B-LCL APCs alone were observed in any of the patients. On the other hand, T-cell lines from all three patients responded equally well to IL-2 (34,581 Ϯ 671, 27,868 Ϯ 672, and 33,570 Ϯ 1,457 cpm and SI values of 68, 46, and 59 for patients P1, P2, and P3, respectively). These results indicated that the T-cell proliferation was specific to HCV antigens but not to nonrelated protein (CAT) or to EBV-derived viral antigens (B-LCL APCs alone). It was not understood why T-cell line P3 failed to respond to autologous APCs. To test whether B-LCL-P3 APCs were functional, they were cultured with T-cell lines from two responders, P1 (HLA-DR compatible) and P2 (HLA-DR incompatible). An additional experiment was performed to stimulate P3 T cells with P1 B APCs (HLA-DR compatible). Figure 4 showed that B-LCL980-P3 did stimulate T cells from HLA-DR-compatible (P1) (6,710 Ϯ 321 cpm; SI ϭ 13) patients but not from HLA-DR-incompatible (P2) (791 Ϯ 138 cpm; SI ϭ 1.6) patients, indicating that B-LCL-P3 APCs were functional and that the presentation was HLA restricted. Again, the P1 B APCs (HLA-DR compatible) failed to stimulate T-cell line P3. To further assess the efficacy of antigen presentation by B-LCL980-P1 and B-LCL980-P2, the number of APCs used to stimulate autologous T cells was titrated. The results indicated that as few as 10 4 APCs were sufficient to induce significant T-cell proliferation (7,434 Ϯ 560 and 6,580 Ϯ 401 cpm and SI values of 15 and 11 for P1 and P2, respectively) (Fig. 5) . Usually, 10
5 APCs produced maximal proliferation, but further increases in APC numbers resulted in no substantial additional increase in T-cell proliferation (data not shown).
Bystander presentation. Theoretically, some B cells may present exogenous antigens (bystander presentation) by reabsorbing and processing antigens that were secreted into the culture medium by transfected cells or shed by adjacent dead or dying cells during the time of culture. To test this possibility, 5 ϫ 10 5 untransfected B-LCL-P1 APCs were precultured with an equal number of allogeneic transfected APCs (B-LCL980-P2, HLA mismatched) in 1 well of a 24-well culture plate for various periods. Two hundred thousand APCs from the mixed culture were then tested for stimulation of autologous T cells (P1) as described above. As shown in Fig. 6A , the untransfected B-LCL-P1 APCs that had been precultured with allogeneic B-LCL980-P2 APCs were incapable of inducing T-cell proliferation above background levels. One reason for this result could be that the core protein is retained in the ER and not secreted to the culture medium, at least not at a level detectable by immunoblotting. Nevertheless, the medium should contain some antigens that were released from the dead cells. To further address this question, 10 6 untransfected B-LCL APCs were cultured for 3 days in the presence of cell lysate from 10 7 transfected COS cells, which was prepared by repeatedly freeze-thawing COS980 cells in PBS, then passing the cells through a sterile 25-gauge needle. The cell lysate prepared from untransfected COS7 cells was used as a negative control. As shown in Fig. 6B , presentation of exogenous antigens in the form of cell lysate could induce only weak T-cell proliferative responses (3,338 Ϯ 272 cpm; SI ϭ 6.6) and the level was just about 1/10 of that obtained by using B-LCL980 APCs. Taken together, these results suggested that presentation with intracellularly synthesized rather than reabsorbed exogenous antigens contributed most, if not exclusively, to the observed T-cell proliferation stimulated by B-LCL APCs.
Presentation of endogenous HCV core peptides is leupeptin sensitive. B-LCL-P1 and B-LCL-P2 APCs were precultured in complete medium containing 33, 100, and 300 g of leupeptin/ml for 24 h and then were used for stimulating autologous T cells in the presence of the same concentration of the drug. A clear inhibition of the presentation of core peptides to T cells was seen in both APCs in a dose-dependent manner (Fig.  7) . When leupeptin was added at 300 g/ml, T-cell stimulation was inhibited to a level below background (SI ϭ 2.9) in P2 and to 26% of that in the control (without leupeptin; SI ϭ 32.4) in P1 (SI ϭ 8.5). These data indicated that processing of endogenously synthesized core peptides by B-LCL APCs is leupeptin sensitive.
Presentation of endogenous core peptides requires class II MHC and costimulatory molecules. The efficiency of presen- tation of endogenous peptides is correlated with the surface expression of MHC class II and costimulatory molecules such as B7/BB1 and ICAM-1 on APCs (14, 18, 26, 34) . ICAM-1 was consistently expressed on both large (activated) and small (resting) B cells (26) , while expression of B7 was found only on activated B cells (26, 34) . In this study, we determined the relative roles of HLA class I, HLA class II, and B7 in the activation of in vivo primed T cells. As shown in Fig. 8 , addition of the soluble MAbs to class II (L243, DR) (50) to the cultures led to the complete inhibition of T-cell proliferation, whereas a MAb to HLA class I (LW6/32) (50) had no substantial inhibitory effects (15.2 and 18.6% inhibition relative to the control responses for P1 and P2, respectively). These findings were consistent with the phenotype analyses showing that more than 90% of proliferating cells were CD4 ϩ CD8 Ϫ T cells (data not shown). In addition, a MAb to BB1 also inhibited T-cell pro- liferation significantly (for P1; 93.5% inhibition relative to the control response) or even completely (for P2).
DISCUSSION
The capacity of B-lymphoblastoid cells for presenting endogenous HCV core peptides to autologous T cells has been investigated by stimulation of patient-derived core-specific Tcell lines. B-LCL APCs expressing the endogenous viral antigens were found to be highly effective restimulators of in vivoprimed T cells. The endogenous presentation of core peptides by B-LCL APCs is leupeptin sensitive and requires class II MHC and B7/BB1 molecules. CD4 ϩ (Th) and CD8 ϩ (CTL) T cells recognize antigenic peptides in association with MHC class II and class I molecules, respectively, expressed on APCs (57). Classically, presentation of endogenous antigens is mediated by MHC class I molecules, while the exogenous antigens are presented by MHC class II molecules (47, 59) . However, accumulating reports have evidenced that MHC class II molecules can also present endogenous viral antigens such as HBsAg (31), influenza A matrix protein (39), and measles virus-derived hemagglutinin (HA) antigen to CD4 ϩ T cells. Extending these findings, we show here that HCV core protein can also be presented through the HLA class II (DR) pathway to CD4 ϩ T cells. T-cell proliferation is completely inhibited by addition to the culture of a MAb to HLA class II (DR) but not of a MAb to HLA class I antigens. This is consistent with the results of phenotypic analysis, showing that most of the proliferating cells are CD4 ϩ CD8 Ϫ T cells (more than 90%). Importantly, presentation of endogenous HCV peptides by B-LCL APCs is very efficient, since as few as 10 4 cells are capable of stimulating significant T-cell proliferation. It is clear that the significant stimulatory effects of B-LCL APCs are not due to bystander presentation with exogenous proteins that are secreted or shed by the adjacent antigen-expressing APCs, since untransfected B-LCL APCs cocultured with allogeneic (HLA-DR mismatched) B-LCL980 APCs are unable to stimulate T cells above background levels. Presentation with exogenous cellular antigens produces only a weak response (Fig. 6B) and requires the presence of COS980 lysate from 10 times more cells. This, however, never occurred in the B-cell cultures, since the viability of B-LCL APCs is always more than 90% and only fewer than 10% of cells are dead or dying. A quantitative comparison by Calin-Laurens et al. (8) has shown that the presentation of endogenous antigen could be 160,000-fold more efficient than that of the exogenous counterparts. Since in vitro proliferation of HCV-specific T cells usually requires 1 to 10 g of recombinant proteins/ml (6, 20, 33) , such amounts would be expected to be much larger than those needed for endogenous presentation (8) . In this study, one of our three patients failed to show T-cell proliferation despite the presence of HCV-specific antibodies. This is not due to defective T-cell function, as the T cells show a response to IL-2 similar in magnitude to that of other two responders. Inefficiency on the part of the B-LCL APCs can also be excluded because these transfected cells are capable of activating, though suboptimally, an HLA-DR matched T-cell line (P1). Nevertheless, since P3 is HCV antibody positive and since production of antibody specific to protein antigens usually needs the help delivered by CD4
ϩ T helper cells (52) , P3 must have specific CD4
ϩ T cells to help B cells. One explanation could be that the polyclonal T-cell lines sometimes lose specificity because the nonspecific cells sometimes grow faster or the avidity to the epitope might change (1) . The maintenance of T-cell specificity is also associated with the peptide concentration in the culture (2) .
It is well documented that the endosome/lyososome compartments are the site of loading of MHC class II molecules with endogenous peptides (25, 28, 36) , and they might be involved in the hydrolytic digestion of endogenous HCV polypeptides and the consequent binding of processed peptides with MHC class II molecules. The core protein contains two hydrophobic domains (55) , and the COOH-terminal hydrophobic fragment (aa 171 to 187) is considered responsible for the cytoplasmic retention of the protein (43) . Analysis by immunoelectron microscopy has shown that core antigen is distributed along the ER membrane or in the cisternae (38) . Supporting these findings, our results demonstrate that the core antigen is well colocalized with an intrinsic ER membrane protein. The fact that core protein usually exhibits strong cy- toplasmic staining in our study and others' (27, 38, 43) studies suggests that there is high expression and/or retention of the protein in transfected cells. It seems likely that the core protein in association with the ER membrane is selectively removed by autophagy during cell remodeling to generate an autophagosome (19). This intermediate vesicle might then fuse with endosome/lysosome compartments to initiate the process for hydrolytic digestion of the "excessive" proteins. Another route for endogenous core protein traveling may also use endocytosis, since the protein can be found on the cell surface when unfixed cells are used (data not shown). The core polypeptide is a basic protein and can bind avidly with other negatively charged surface molecules once the protein is secreted to the surface by an as-yet-unknown mechanism. The core antigen can then be endocytosed by spontaneous internalization of the cell membrane and transported to the site for MHC class II loading. The processing of endogenous core peptides in endosome/lysosome compartments is evidenced by our results in leupeptin inhibition experiments. Leupeptin is a commonly used cysteine/serine protease inhibitor that blocks degradation of the protein in the endocytic pathway. Therefore, it also blocks the degradation of the MHC class II-associated invariant chain. Limited studies have also suggested a nonendosomal processing pathway that involves the proteolytic degradation of endogenous proteins and consequent binding with MHC class II molecules in the ER compartment (39, 49) . So far, this pathway has not been well characterized. In fact, the newly synthesized MHC class II heterodimers (␣␤) are competitively occupied by the invariant chain (Ii), and the complexes do not disassociate until they reach the acidic environment of the endosomal/lysosomal compartment (23), thus preventing binding with endogenous peptides in the ER. Whether MHC class II loading with HCV endogenous peptides can occur physiologically in a nonendosomal compartment such as the ER in "professional" APCs remains to be established.
A solid base of evidence has confirmed that optimal activation of T cells requires, in addition to the first signal for triggering the CD3-T-cell receptor complex to initiate the activation process, a second signal that is delivered by APC-mediated accessory molecules such as B7/BB1, ICAM-1, VCAM-1, or LFA (all of which belong to the Ig supergene family) (14, 18, 26, 34) . B7/BB1 is one of the most important costimulatory ligands and functions by interacting with its receptor, CD28/ CTLA-4, expressed on the surfaces of T cells. The triggering of CD28 by B7/BB1 is found to be especially involved in IL-2 production and proliferation (24, 34) . Furthermore, the presence of B7/BB1 during the cross-linking of T-cell receptors with antigenic peptide-MHC class II complex is thought to play a critical role in preventing T-cell clonal inactivity or anergy (48) . Since B7/BB1 is constitutively expressed on EBV-transformed B-cell lines (58) , the molecule may contribute to the efficient presentation of endogenous HCV peptides in our assays. This possibility is supported by the significant or even complete inhibition of T-cell activation by a MAb to BB1. Although other adhesion and costimulatory molecules may possibly provide costimulatory signals, such effects appear to be less efficient or to depend on the synergistic expression of B7/BB1 for costimulation of in vivo-primed T cells. This is consistent with the previous observations that ICAM-1 and VCAM-1 regulate resting CD4 ϩ T cells preferentially, whereas B7/BB1 costimulates antigen-primed T cells most potently. LFA-3 has a behavior similar to that of B7/BB1, but it is less efficient (14) .
Although endogenous antigens are classically presented through the class I MHC pathway to stimulate CD8 T cells, we demonstrate here that core antigens endogenously synthesized in B cells can also enter the class II MHC pathway for presentation and efficiently induce an autologous CD4 ϩ T-cell reaction. These findings provide useful information for the design of new approaches, such as DNA-mediated vaccination, for augmenting both helper and CTL responses. Importantly, data from a recent in vivo study have shown that subcutaneous immunization of chimpanzees with transfected autologous EBVimmortalized B cells expressing a tumor antigen induced both CD4 and CD8 antitumor T-cell responses (40) . Since the protocols for de vivo gene delivery into the primary B cells have been already described and tested for somatic gene therapy in a murine model (54) and a clinical trial (5), delivery of HCV genes or other viral and tumor immunodominant genes into the B-cell compartment may serve as an alternative approach in this regard. These potential applications await further examination.
